Epinephrine Auto-injector to Return

AUVI-Q is a prescription medication indicated for treatment in people who are at risk, or have a history, of life-threatening allergic reactions.

Kaleo has announced the return of AUVI-Q (epinephrine injection, USP) auto-injector to the United States in 2017. AUVI-Q is a prescription medication indicated for treatment in people who are at risk, or have a history, of life-threatening allergic reactions, including anaphylaxis.

The compact epinephrine auto-injector will be reintroduced with industry-first features, including a voice prompt system that guides users with step-by-step instruction of the delivery process, and a needle that automatically retracts after administration.

AUVI-Q’s revamped manufacturing and quality system will help ensure reliable and accurate epinephrine dose delivery in life-threatening allergic emergencies.

“For the millions affected by life-threatening food allergies, an epinephrine auto-injector serves as a lifeline,” said James. R Baker, Jr., MD, Food Allergy Research and Education CEO and chief medical officer, in a press release. “These lifesaving devices must be accessible and affordable, and Americans should have options when it comes to selecting the right auto-injector for their family.”

Kaleo’s priority is to deliver AUVI-Q to the US market as an alternative epinephrine auto-injector option, and the company is working to ensure that patients can have affordable access to AUVI-Q regardless of insurance coverage.